These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18945567)

  • 1. [Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumors].
    Kanyinda-K JM; Samalin E; Sebah H; Gallix B; Ychou M
    Gastroenterol Clin Biol; 2008 Dec; 32(12):989-91. PubMed ID: 18945567
    [No Abstract]   [Full Text] [Related]  

  • 2. Rectal neuroendocrine tumor presenting as a polyp with hepatic metastases.
    Meriam S; Trad D; Jouini R; Haddad D; Ouakaa A
    Gastrointest Endosc; 2019 Oct; 90(4):688-689. PubMed ID: 31375265
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
    Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
    J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract]   [Full Text] [Related]  

  • 7. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Yang F; Jin C; Fu D
    N Engl J Med; 2014 Oct; 371(16):1556. PubMed ID: 25317883
    [No Abstract]   [Full Text] [Related]  

  • 8. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Ozdemir N; Yazici O; Zengin N
    N Engl J Med; 2014 Oct; 371(16):1555-6. PubMed ID: 25317882
    [No Abstract]   [Full Text] [Related]  

  • 9. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ruszniewski P
    N Engl J Med; 2014 Oct; 371(16):1556-7. PubMed ID: 25317881
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroendocrine cancer: CLARINET: new option for NETs.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073004
    [No Abstract]   [Full Text] [Related]  

  • 11. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
    Khagi S; Saif MW
    JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
    Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
    Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
    Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
    Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Complete and sustained remission of liver metastases from neuroendocrine tumor with somatostatin analogue therapy].
    Raizer G; Igaz P; Pregun I; Dabasi G; Rácz K
    Orv Hetil; 2011 Mar; 152(10):407-10. PubMed ID: 21354958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
    Colao A; Faggiano A; Pivonello R
    Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanreotide slows growth of neuroendocrine cancer.
    Cancer Discov; 2014 Oct; 4(10):OF3. PubMed ID: 25274694
    [No Abstract]   [Full Text] [Related]  

  • 18. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumour vanishes.
    Todd JF; Meeran K
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroendocrine cancer: CLARINET: new option for NETS.
    Hutchinson L
    Nat Rev Endocrinol; 2014 Oct; 10(10):577. PubMed ID: 25069467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.